Caris Life Sciences, Inc. CAI
What this company does
Written from the business description in Caris Life Sciences, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 3 March 2026. Every sentence was checked against that document before publication.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Not applicable: equity was negative in this period, so return on equity has no meaning.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue $B | 0.8 | 0.4 | 0.3 |
| Operating income $B | 0.0 | −0.3 | −0.3 |
| EBITDA $B | 0.1 | −0.2 | −0.3 |
| Income tax $B | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.3 | −0.3 |
| Free cash flow $B | 0.1 | −0.3 | −0.3 |
| EPS, diluted $ | −3.22 | −10.66 | −13.24 |
| Dividend / sh $ | · | · | · |
| Payout % | · | · | · |
| ROE % | · | · | · |
| Shares out B | 0.28 | 0.04 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 3 of 19 fiscal years. 66 checks could not be computed.